Overall, the results of these in vivo experiments point out that even though IDO1 might be involved in suppressing antitumoral CD4+ and CD8+ T cell responses, targeted blocking of IDO1, especially at the later stages of the disease, does not reverse T cell suppression or control leukemia development in the TCL1 AT model. Here, IDO1 is linked to leukemia.